Innocoll and durect announce u.s. launch of posimir®

Posimir® is now commercially available in the u.s. for the treatment of post-surgical pain in adults following arthroscopic subacromial decompression surgery durect recently received an $8 million milestone payment for a new patent issuance and has now earned a $2 million milestone payment for first commercial sale of posimir athlone, ireland and cupertino, calif. , sept. 26, 2022 /prnewswire/ -- innocoll pharmaceuticals limited, a commercial-stage biotechnology  company and portfolio business of gurnet point capital, and durect corporation (nasdaq: drrx) today announced the recent commercial launch of posimir® (bupivacaine solution) in the united states.
DRRX Ratings Summary
DRRX Quant Ranking